LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
ELI LILLY & Co
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$1240.34−16.69 (-1.33%)
Close on Oct 19, 2026
- Market cap
- $1.11T
- P/E (TTM)
- 41.6
- Dividend yield
- 0.50%
ELI LILLY & Co revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reportable Segment | $65.18B | $45.04B | $34.12B | $28.54B | – | – | – | – | – | – | 100.0% | +44.7% |
| Animal health products | – | – | – | – | – | – | – | – | $3.09B | $3.16B | – | – |
| Human pharmaceutical products | – | – | – | – | – | – | – | – | $19.79B | $18.06B | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product revenue | $60.96B | $40.75B | $28.81B | $25.46B | $25.96B | $22.69B | $20.38B | $19.87B | $18.78B | $20.39B | 93.5% | +49.6% |
| Collaboration and other revenue | $4.22B | $4.30B | $5.31B | $3.08B | $2.36B | $1.85B | $1.94B | $1.63B | $1.20B | $833.70M | 6.5% | -1.7% |
| Jardiance | $3.43B | $3.34B | $2.75B | $2.07B | $1.49B | $1.15B | $944.20M | $658.30M | $447.50M | $201.90M | 5.3% | +2.7% |
| Erbitux | – | – | – | – | – | – | – | $635.30M | $645.90M | $687.00M | – | – |
| Effient | – | – | – | – | – | – | – | – | – | $535.20M | – | – |
| Erbitux API [Member] | – | – | – | – | – | – | – | – | – | $0 | – | – |
| Basaglar | – | $676.90M | $728.30M | $760.40M | $892.50M | $1.12B | $1.11B | $801.20M | $432.10M | $86.10M | – | – |
| Trajenta | – | – | $386.90M | $383.70M | $372.50M | $358.50M | $590.60M | $574.70M | $537.90M | $436.60M | – | – |
| Collaboration and other revenue associated with prior period transfers of intellectual property | – | – | $191.60M | $163.40M | $175.00M | $135.60M | $301.50M | $303.20M | $144.90M | $146.10M | – | – |
| Erbitux, Collaboration and Other Revenue | – | – | – | – | – | – | – | $99.20M | $97.70M | $100.00M | – | – |
| Erbitux, Product | – | – | – | – | – | – | – | $536.10M | $548.20M | $587.00M | – | – |
| Olumiant | – | $957.40M | $922.60M | $830.50M | $1.12B | $638.90M | $426.90M | $202.50M | $45.80M | – | – | – |
| Tyvyt | – | $526.00M | $393.40M | $293.30M | $418.10M | $308.70M | $134.00M | – | – | – | – | – |
| Bamlanivimab | – | – | – | – | – | $871.20M | – | – | – | – | – | – |
| COVID-19 antibodies | – | $0 | $0 | $2.02B | $2.24B | $871.20M | – | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $43.48B | $30.38B | $21.79B | $18.19B | $16.81B | $14.23B | $12.72B | $12.39B | $11.41B | $11.51B | 66.7% | +43.1% |
| Outside U.S. | $21.70B | $14.67B | $12.33B | $10.35B | $11.51B | $10.31B | $9.60B | $9.10B | $8.56B | – | 33.3% | +47.9% |
| Europe | $11.56B | $6.92B | $6.18B | $4.30B | $4.78B | $4.19B | $3.77B | $3.66B | $3.39B | $3.77B | 17.7% | +67.0% |
| Rest of world | $6.06B | $4.27B | $2.95B | $2.85B | – | – | – | – | – | – | 9.3% | +41.8% |
| Japan | $2.13B | $1.82B | $1.67B | $1.75B | $2.37B | $2.58B | $2.55B | $2.41B | $2.34B | $2.33B | 3.3% | +17.5% |
| China | $1.95B | $1.66B | $1.54B | $1.45B | $1.66B | $1.12B | $939.40M | $750.80M | – | – | 3.0% | +17.5% |
| Other foreign countries | – | – | $2.95B | $2.85B | $2.70B | $2.42B | $2.34B | $2.28B | $2.83B | $3.62B | – | – |
| Outside U.S. | – | – | – | – | – | – | – | $10.68B | $10.09B | $9.72B | – | – |
From the segment and revenue-disaggregation notes of Eli Lilly's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.